cadralazine has been researched along with Blood Pressure, High in 27 studies
cadralazine: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Arterial diameter, blood flow, and vascular resistance of the common carotid artery were studied together with the carotido-femoral pulse wave velocity in men with sustained essential hypertension before and after acute oral administration of either captopril or a hydralazinelike agent, cadralazine." | 7.67 | Carotid arterial hemodynamics in hypertension: acute administration of captopril or cadralazine. ( Billaud, EB; Lacolley, PJ; Laurent, ST; Safar, ME, 1989) |
| "Forearm venous tone and brachial artery hemodynamics, including determinations of the arterial diameter and compliance by the use of pulsed Doppler systems, were measured in 16 patients with sustained essential hypertension before and after acute oral cadralazine dosing." | 7.67 | Effect of cadralazine on brachial artery hemodynamics and forearm venous tone in essential hypertension. ( Bouthier, JA; Curien, ND; Levenson, JA; London, GM; Safar, ME; Simon, AC, 1986) |
| "Cadralazine is a peripheral arteriolar vasodilator which, unlike hydralazine or dihydralazine, has a protected hydrazino group." | 6.38 | Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. ( Clissold, SP; McTavish, D; Young, RA, 1990) |
| "This study compared the effects of 1 year of monotherapy with a calcium-channel antagonist (nilvadipine; NIL), an angiotensin-converting enzyme (ACE) inhibitor (temocapril; TEM), or a new vasodilator (cadralazine; CAD) on left ventricular (LV) hypertrophy in essential hypertension." | 5.08 | The effects of long-term treatment on left ventricular hypertrophy in patients with essential hypertension: relation to changes in neurohumoral factors. ( Inoue, H; Oh-hashi, S; Takata, M; Tomita, S; Ueno, H; Yasumoto, K, 1997) |
| "Common carotid blood flow and cold pressor test were evaluated in 16 patients with sustained essential hypertension before and after 30 days treatment with the converting enzyme inhibitor Enalapril (20 mg)." | 5.07 | An indirect evaluation of the effect of the autonomic nervous system following converting enzyme inhibition in hypertension. ( Asmar, RG; Benetos, A; Darne, B; Laurent, S; Safar, ME, 1992) |
| "The antihypertensive effects of the hydralazine-related compound cadralazine (2-(3-[6-(2-hydroxypropyl)ethylamino]pyridazinyl)ethyl carbazate, ISF 2469), were investigated in 16 patients with primary hypertension concurrently treated with beta-blockers and diuretics." | 5.06 | Acute systemic and renal haemodynamic effects and long-term antihypertensive action of cadralazine in patients pretreated with beta-blockers and diuretics. ( Andersson, OK; Granerus, G; Hedner, T; Persson, B; Wysocki, M, 1987) |
| "Arterial diameter, blood flow, and vascular resistance of the common carotid artery were studied together with the carotido-femoral pulse wave velocity in men with sustained essential hypertension before and after acute oral administration of either captopril or a hydralazinelike agent, cadralazine." | 3.67 | Carotid arterial hemodynamics in hypertension: acute administration of captopril or cadralazine. ( Billaud, EB; Lacolley, PJ; Laurent, ST; Safar, ME, 1989) |
| "The antihypertensive activity of a new arterial dilator, cadralazine, was evaluated in 40 patients with mild-to-moderate arterial hypertension." | 3.67 | Antihypertensive activity of a new vasodilator, cadralazine, administered alone or in combination with a beta-blocker. ( Buoninconti, R; Motolese, M, 1985) |
| "Forearm venous tone and brachial artery hemodynamics, including determinations of the arterial diameter and compliance by the use of pulsed Doppler systems, were measured in 16 patients with sustained essential hypertension before and after acute oral cadralazine dosing." | 3.67 | Effect of cadralazine on brachial artery hemodynamics and forearm venous tone in essential hypertension. ( Bouthier, JA; Curien, ND; Levenson, JA; London, GM; Safar, ME; Simon, AC, 1986) |
| "Arterial hypertension is often associated with plasma volume contraction and hemoconcentration, which negatively affect the vascular flow resistance and microcirculation." | 2.68 | Hemorheologic effects of vasodilation in essential hypertension. ( Andersson, OK; Bagge, U; Braide, M; Persson, B; Wysocki, M, 1996) |
| "Cadralazine (ISF 2469) was administered to 24 hypertensive patients in single oral doses of 7." | 2.65 | Cadralazine (ISF 2469): dose-related antihypertensive activity after single oral administration to patients. ( Catalano, M; Libretti, A; Parini, J, 1983) |
| "Cadralazine is a peripheral arteriolar vasodilator which, unlike hydralazine or dihydralazine, has a protected hydrazino group." | 2.38 | Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. ( Clissold, SP; McTavish, D; Young, RA, 1990) |
| " The terminal half-life of elimination (3." | 1.28 | Pharmacokinetics of cadralazine in a large group of hypertensive patients chronically treated with cadralazine: advantage over a conventional study in a small group of patients. ( Chanard, J; Cordonnier, D; Darragon, T; Dubois, JP; Ducret, F; Glorioso, M; Grouberman, D; Lecaillon, JB; Motolese, M; Racine, A, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (66.67) | 18.7374 |
| 1990's | 9 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Strocchi, E | 1 |
| Costa, FV | 2 |
| Caldari, R | 1 |
| Malini, PL | 1 |
| Marata, AM | 1 |
| Parini, J | 5 |
| Ambrosioni, E | 2 |
| Catalano, M | 2 |
| Libretti, A | 2 |
| Angelino, PF | 2 |
| Bensoni, M | 2 |
| Gastaldo, D | 2 |
| Minelli, M | 1 |
| Parini, M | 1 |
| Lavezzaro, GC | 2 |
| Noussan, P | 1 |
| Antonicelli, R | 1 |
| Savonitto, S | 2 |
| Tomassini, PF | 1 |
| Gambini, C | 1 |
| Sardina, M | 1 |
| Paciaroni, E | 1 |
| Wysocki, M | 3 |
| Andersson, OK | 2 |
| Persson, B | 3 |
| Bagge, U | 1 |
| Braide, M | 1 |
| Ueno, H | 2 |
| Takata, M | 2 |
| Tomita, S | 2 |
| Oh-hashi, S | 1 |
| Yasumoto, K | 2 |
| Inoue, H | 2 |
| Tomoda, F | 1 |
| Asmar, RG | 1 |
| Benetos, A | 1 |
| Darne, B | 1 |
| Laurent, S | 4 |
| Safar, ME | 5 |
| Caponnetto, S | 1 |
| Valvo, E | 1 |
| Mocarelli, P | 1 |
| Alberti, D | 1 |
| Lecaillon, JB | 1 |
| Dubois, JP | 1 |
| Darragon, T | 1 |
| Motolese, M | 2 |
| Racine, A | 1 |
| Ducret, F | 1 |
| Grouberman, D | 1 |
| Cordonnier, D | 1 |
| Chanard, J | 1 |
| Glorioso, M | 1 |
| McTavish, D | 1 |
| Young, RA | 1 |
| Clissold, SP | 1 |
| Mulder, H | 1 |
| London, GM | 2 |
| Bouthier, JA | 2 |
| Levenson, JA | 2 |
| Lacolley, PJ | 1 |
| Laurent, ST | 1 |
| Billaud, EB | 1 |
| Yuhara, M | 1 |
| Salvadeo, A | 1 |
| Villa, G | 1 |
| Segagni, S | 1 |
| Piazza, V | 1 |
| Picardi, L | 1 |
| Romano, M | 2 |
| Buoninconti, R | 1 |
| Granerus, G | 2 |
| Hedner, T | 2 |
| Andersson, O | 1 |
| Curien, ND | 1 |
| Simon, AC | 2 |
| London, G | 2 |
| Safar, M | 2 |
| Bouthier, JD | 1 |
| De Luca, N | 1 |
| Haglund, K | 1 |
| Dahlqvist, R | 1 |
| Emilsson, H | 1 |
| Englund, G | 1 |
| Lacolley, P | 1 |
| Borghi, C | 1 |
| Mussi, A | 1 |
1 review available for cadralazine and Blood Pressure, High
| Article | Year |
|---|---|
Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.
Topics: Antihypertensive Agents; Humans; Hypertension; Pyridazines | 1990 |
12 trials available for cadralazine and Blood Pressure, High
| Article | Year |
|---|---|
Comparison of the antihypertensive activity of cadralazine (ISF 2469) and dihydralazine during chronic treatment.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Dihydralazine; Female; Headache; Heart Rat | 1983 |
Cadralazine (ISF 2469): dose-related antihypertensive activity after single oral administration to patients.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Dr | 1983 |
Hemodynamic effects of cadralazine or chlorthalidone in verapamil-treated elderly hypertensives.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Double-Blind Method; Drug Therapy, Co | 1994 |
Hemorheologic effects of vasodilation in essential hypertension.
Topics: Antihypertensive Agents; Blood Viscosity; Cross-Over Studies; Double-Blind Method; Hematocrit; Hemod | 1996 |
The effects of long-term treatment on left ventricular hypertrophy in patients with essential hypertension: relation to changes in neurohumoral factors.
Topics: Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atrial | 1997 |
Different effects of temocapril and cadralazine on electrocardiographic voltages and left ventricular mass in patients with essential hypertension.
Topics: Aged; Antihypertensive Agents; Echocardiography; Electrocardiography; Female; Humans; Hypertension; | 1999 |
An indirect evaluation of the effect of the autonomic nervous system following converting enzyme inhibition in hypertension.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Autonomic Nervous System; Blood Pressure; Carotid A | 1992 |
Cadralazine versus prazosin as second-step treatment in hypertensive patients on beta-blockers: a randomized multicentre study. The Italian Multicentre Study Group.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Female; Humans; Hypertension; Male; Middle Aged; Prazosin; | 1991 |
Acute systemic and renal haemodynamic effects and long-term antihypertensive action of cadralazine in patients pretreated with beta-blockers and diuretics.
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; Cardiac | 1987 |
Systemic and renal hemodynamic effects of single oral doses of cadralazine and long term antihypertensive effects of cadralazine in patients receiving therapy with beta-blockers and diuretics.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Antihypertensive Agents; Diuretics; Double-Blind | 1986 |
Cadralazine and chlorthalidone as a second-step drug with atenolol in hypertensive patients: differences in blood pressure control during exercise.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Chemical Analysis; Blood Pressure; Body Weight; Chlo | 1986 |
Controlled clinical trial of cadralazine as a second-step drug in the treatment of hypertension.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Clinical Trials as Topic; Drug Th | 1985 |
14 other studies available for cadralazine and Blood Pressure, High
| Article | Year |
|---|---|
[Open pilot study of the activity and tolerability of cadralazine in hypertensive patients resistant to other therapy].
Topics: Adolescent; Adult; Female; Humans; Hypertension; Male; Middle Aged; Pyridazines; Vasodilator Agents | 1982 |
[Effects of cadralazine (ISF 2469) on water-sodium balance and on essential arterial hypertension].
Topics: Adult; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Pyridazines; Vasodilator Agent | 1981 |
Pharmacokinetics of cadralazine in a large group of hypertensive patients chronically treated with cadralazine: advantage over a conventional study in a small group of patients.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Body Weight; Chromatography, High Pressure Liquid; | 1991 |
Conversion of drug-induced SLE-syndrome by the vasodilating agent cadralazine.
Topics: Adult; Blood Pressure; Humans; Hydralazine; Hypertension; Lupus Erythematosus, Systemic; Male; Pyrid | 1990 |
Brachial artery cross-sectional area and distensibility before and after arteriolar vasodilatation in men with sustained essential hypertension.
Topics: Adult; Aged; Blood Pressure; Brachial Artery; Female; Hemodynamics; Humans; Hypertension; Male; Midd | 1987 |
Carotid arterial hemodynamics in hypertension: acute administration of captopril or cadralazine.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Captopril; Carotid Arteries; Female; Hemodynamics; H | 1989 |
[Clinical application of vascular smooth muscle relaxants in the treatment of hypertension].
Topics: Guanidines; Humans; Hydralazine; Hypertension; Nitroglycerin; Parasympatholytics; Pinacidil; Pyridaz | 1989 |
Cadralazine, a new vasodilator, in addition to a beta-blocker for long-term treatment of hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Drug Therapy, Combinati | 1985 |
Antihypertensive activity of a new vasodilator, cadralazine, administered alone or in combination with a beta-blocker.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combinati | 1985 |
Effect of cadralazine on brachial artery hemodynamics and forearm venous tone in essential hypertension.
Topics: Administration, Oral; Adult; Blood Flow Velocity; Blood Pressure; Brachial Artery; Drug Evaluation; | 1986 |
[Non-invasive study of the role of carotid distension in the baroreflex response to the arteriolar vasodilator cadralazine in essential hypertension].
Topics: Adult; Arm; Arterioles; Blood Pressure; Carotid Arteries; Female; Heart Rate; Humans; Hypertension; | 1986 |
Cardiac hypertrophy and arterial distensibility in essential hypertension.
Topics: Adult; Aged; Arteries; Blood Flow Velocity; Cardiomegaly; Humans; Hypertension; Middle Aged; Nifedip | 1985 |
Cadralazine pharmacokinetics--a pilot study.
Topics: Adult; Antihypertensive Agents; Biological Availability; Humans; Hypertension; Middle Aged; Pyridazi | 1988 |
Hemodynamics of the carotid artery after vasodilation in essential hypertension.
Topics: Adult; Blood Pressure; Brachial Artery; Carotid Arteries; Female; Hemodynamics; Humans; Hypertension | 1988 |